Rallybio (RLYB) vs Zhengye Biotechnology (ZYBT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Rallybio (RLYB) has outperformed Zhengye Biotechnology (ZYBT) over the past year, gaining 268.7% versus a loss of 62.7%. Rallybio is the larger company by market cap ($90.9 million vs $83.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RLYB | ZYBT |
|---|---|---|
| Share price | $17.11 | $1.76 |
| Market cap | $90.87M | $83.41M |
| 1-day change | +0.68% | +53.06% |
| YTD return | +209.58% | -0.01% |
| 1-year return | +268.71% | -62.67% |
| 5-year return | -86.32% | — |
| P/E ratio (TTM) | 2.14 | — |
| EPS (TTM) | $8.01 | $-0.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.57 | $8.01 |
| 52-week low | $3.67 | $0.616 |
| Distance from 52-week high | -2.67% | -78.03% |
| Average volume | 21.33K | 5.10M |
| Shares outstanding | 5.31M | 47.39M |
| Employees | 7 | 269 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RLYB has outperformed ZYBT by 331.4 percentage points over the past year.
About Rallybio
RLYB stock →Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About Zhengye Biotechnology
ZYBT stock →Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in the People's Republic of China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs, as well as monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine.
Health Care · Biotechnology: Pharmaceutical Preparations · 269 employees
RLYB vs ZYBT FAQ
Which is bigger, Rallybio or Zhengye Biotechnology?
Rallybio (RLYB) is larger, with a market capitalization of $90.87M compared with $83.41M for Zhengye Biotechnology (ZYBT).
Which stock has performed better over the past year, RLYB or ZYBT?
RLYB returned +268.71% over the past 12 months, compared with -62.67% for ZYBT (price return, excluding dividends). Past performance does not predict future results.
Are Rallybio and Zhengye Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.